Julien Bezin1, Nicholas Moore2, Yohann Mansiaux3, Philippe Gabriel Steg4, Antoine Pariente5. 1. University Bordeaux, Institut National de la Santé et de la Recherche Médicale (INSERM), Bordeaux Population Health Research Center, Team Pharmacoepidemiology, Unité Mixte de Recherche (UMR) 1219, Bordeaux, France. Electronic address: julien.bezin@u-bordeaux.fr. 2. University Bordeaux, Institut National de la Santé et de la Recherche Médicale (INSERM), Bordeaux Population Health Research Center, Team Pharmacoepidemiology, Unité Mixte de Recherche (UMR) 1219, Bordeaux, France; Centre Hospitalier Universitaire (CHU) de Bordeaux, Bordeaux, France; Bordeaux PharmacoEpi, INSERM CIC 1401, Bordeaux, France. 3. University Bordeaux, Institut National de la Santé et de la Recherche Médicale (INSERM), Bordeaux Population Health Research Center, Team Pharmacoepidemiology, Unité Mixte de Recherche (UMR) 1219, Bordeaux, France. 4. FACT (French Alliance for Cardiovascular Clinical Trials), Département Hospitalo-Universitaire (DHU) Fibrose Inflammation Remodelage (FIRE), University Paris Diderot, Assistance Publique - Hôpitaux de Paris (AP-HP), INSERM U-1148, Paris, France; National Heart and Lung Institute (NHLI), Institute of Cardiovascular Medicine and Science (ICMS), Royal Brompton Hospital, Imperial College, London, United Kingdom. 5. University Bordeaux, Institut National de la Santé et de la Recherche Médicale (INSERM), Bordeaux Population Health Research Center, Team Pharmacoepidemiology, Unité Mixte de Recherche (UMR) 1219, Bordeaux, France; Centre Hospitalier Universitaire (CHU) de Bordeaux, Bordeaux, France.
Abstract
OBJECTIVES: The benefits of initiating statins in the elderly remains debated. We evaluated the effects of initiating statins in the elderly, according to cardiovascular risk. METHODS: This population-based cohort study used data of the representative sample of the French health care system database for the 2008-2015 period. New users of statins, aged 75 years and older, were dynamically included in the cohort and matched 1:1 to statin nonusers on age, sex, numbers of different drugs dispensed and medical consultations, and cardiovascular history. Patients were classified into 3 cardiovascular risk groups: secondary prevention (history of coronary heart disease), primary prevention with modifiable risk factors (diabetes or cardiovascular medications), and primary prevention without modifiable risk factors (none of the above). Effect of cumulative use of statins on occurrence of acute coronary syndrome or all-cause death was analyzed by using multivariable time-dependent Cox models stratified on cardiovascular risk at inclusion. RESULTS: Among the 7284 patients included, median follow-up was 4.7 years. Cumulative use of statins was associated with a lower risk of outcomes in the primary prevention with modifiable risk factors group (adjusted hazard ratio 0.93 per year of use; 95% confidence interval, 0.89-0.96; P < .01) and in the secondary prevention group (0.75; 0.63-0.90; P < .01), but not in the primary prevention without modifiable risk factors group (1.01; 0.86-1.18; P = .92). CONCLUSIONS: Statin treatment was not associated with a reduction in acute coronary syndrome or all-cause death in elderly without modifiable cardiovascular risk factor treated in primary prevention.
OBJECTIVES: The benefits of initiating statins in the elderly remains debated. We evaluated the effects of initiating statins in the elderly, according to cardiovascular risk. METHODS: This population-based cohort study used data of the representative sample of the French health care system database for the 2008-2015 period. New users of statins, aged 75 years and older, were dynamically included in the cohort and matched 1:1 to statin nonusers on age, sex, numbers of different drugs dispensed and medical consultations, and cardiovascular history. Patients were classified into 3 cardiovascular risk groups: secondary prevention (history of coronary heart disease), primary prevention with modifiable risk factors (diabetes or cardiovascular medications), and primary prevention without modifiable risk factors (none of the above). Effect of cumulative use of statins on occurrence of acute coronary syndrome or all-cause death was analyzed by using multivariable time-dependent Cox models stratified on cardiovascular risk at inclusion. RESULTS: Among the 7284 patients included, median follow-up was 4.7 years. Cumulative use of statins was associated with a lower risk of outcomes in the primary prevention with modifiable risk factors group (adjusted hazard ratio 0.93 per year of use; 95% confidence interval, 0.89-0.96; P < .01) and in the secondary prevention group (0.75; 0.63-0.90; P < .01), but not in the primary prevention without modifiable risk factors group (1.01; 0.86-1.18; P = .92). CONCLUSIONS: Statin treatment was not associated with a reduction in acute coronary syndrome or all-cause death in elderly without modifiable cardiovascular risk factor treated in primary prevention.
Authors: Ariela R Orkaby; Jane A Driver; Yuk-Lam Ho; Bing Lu; Lauren Costa; Jacqueline Honerlaw; Ashley Galloway; Jason L Vassy; Daniel E Forman; J Michael Gaziano; David R Gagnon; Peter W F Wilson; Kelly Cho; Luc Djousse Journal: JAMA Date: 2020-07-07 Impact factor: 56.272
Authors: Peter R Sinnaeve; Gregory G Schwartz; Daniel M Wojdyla; Marco Alings; Deepak L Bhatt; Vera A Bittner; Chern-En Chiang; Roger M Correa Flores; Rafael Diaz; Maria Dorobantu; Shaun G Goodman; J Wouter Jukema; Yong-Un Kim; Robert Pordy; Matthew T Roe; Rody G Sy; Michael Szarek; Harvey D White; Andreas M Zeiher; Ph Gabriel Steg Journal: Eur Heart J Date: 2020-06-21 Impact factor: 29.983
Authors: Kamal Awad; Maged Mohammed; Mahmoud Mohamed Zaki; Abdelrahman I Abushouk; Gregory Y H Lip; Michael J Blaha; Carl J Lavie; Peter P Toth; J Wouter Jukema; Naveed Sattar; Maciej Banach Journal: BMC Med Date: 2021-06-22 Impact factor: 8.775
Authors: Emma Ef Kleipool; Johannes An Dorresteijn; Yvo M Smulders; Frank Lj Visseren; Mike Jl Peters; Majon Muller Journal: Heart Date: 2019-11-28 Impact factor: 5.994